Dublin, April 14, 2026 (GLOBE NEWSWIRE) -- The "Protein Engineering for Pharmaceutical Biotechnology (July 7th - July 8th, 2026)" training has been added to ResearchAndMarkets.com's offering.
Enhance your knowledge in protein engineering to understand how to advance therapeutic development and industrial applications.
Protein-based therapeutics have significantly advanced and created new paradigms in disease treatment. Half of the top ten selling drugs in 2023 are protein-based therapeutics.
Protein engineering, a field perfected by nature over billions of years, can now be replicated and customised in the laboratory within weeks. This course aims to equip professionals with the skills to develop more valuable and better-featured proteins, particularly enzymes, for a wide range of pharmaceutical applications.
By understanding and applying the latest advancements in molecular biology, protein chemistry, enzymology, and structural chemistry, attendees will be able to create practical solutions that meet the needs of the pharmaceutical sector. The significance and timelessness of this training are underscored by the 2018 Nobel Prize for Chemistry, awarded for groundbreaking work in protein engineering, highlighting its growing importance and potential to revolutionise various industries.
Who Should Attend:
This course is designed for professionals with a foundational understanding of biochemistry and molecular biology, seeking to deepen their knowledge and understanding in protein engineering, including:
- Biotechnology professionals
- Regulatory affairs professionals
- Pharmaceutical development specialists
- Quality assurance and control officers
- Clinical researchers
- Process development engineers
- Project managers
Key Topics Covered:
Day 1
- Introduction to protein engineering
- Techniques and tools in genetic engineering
- Pharmaceutical applications of protein engineering
- Production of biopharmaceuticals
Day 2
- Ethical and regulatory considerations
- Advances in protein engineering for pharmaceuticals
- Challenges in protein engineering for pharmaceuticals
- Case studies and examples
- Engineering modern drugs and targeted cancer therapy
- Engineering of superantigens for targeted cancer therapy
CPD Hours: 12
Speakers
Sayed Goda
Sayed K Goda, a biochemistry and drug discovery professor, has a robust academic background. He earned a BSc in Chemistry and an MSc in organic chemistry from Cairo University, Egypt. He then pursued a PhD in Biochemistry from the University of Southampton, UK. Recognising the pivotal role of technology management in his field, he obtained an MBA in technology management from the Open University, UK, in 2000. His diverse educational background equips him with a unique perspective and a broad range of skills, making him a valuable asset in the field of biochemistry and drug discovery.
After completing his PhD, Sayed embarked on a leadership journey at the Porton Down establishment in Salisbury, UK, where he served for fourteen years as a senior scientist and a team leader. During that time, he led commercial and medically sensitive research. He employed protein engineering to produce novel commercially and medically important proteins.
For more information about this training visit https://www.researchandmarkets.com/r/un33s0
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
